Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | BRAF |
Variant | R682W |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | BRAF R682W lies within the protein kinase domain of the Braf protein (UniProt.org). R682W has been demonstrated to confer resistance to Tarceva (erlotinib) in the context of EGFR exon 19 deletions in cultured cells (PMID: 27478040), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Oct 2022). |
Associated Drug Resistance | Y |
Category Variants Paths |
BRAF mutant BRAF R682W |
Transcript | NM_004333.5 |
gDNA | chr7:g.140739895G>A |
cDNA | c.2044C>T |
Protein | p.R682W |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001354609.1 | chr7:g.140739895G>A | c.2044C>T | p.R682W | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140739895G>A | c.2044C>T | p.R682W | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|